biopharmapatent

Wednesday, January 30, 2019

A Summary of IP Protection in China’s Biological and Pharmaceutical Sectors

http://www.niuyie.com/a-summary-of-ipr-protection-in-chinas-biological-and-pharmaceutical-sectors/
Posted by Paul Moradian's Pharma blog at 5:19 PM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

LinkedIn

Blog Archive

  • ►  2020 (2)
    • ►  August (1)
    • ►  April (1)
  • ▼  2019 (5)
    • ▼  January (5)
      • A Summary of IP Protection in China’s Biological a...
      • Genentech's Herceptin Patents Asserted Against Sam...
      • Patent term adjustment went beyond the period duri...
      • Supreme Court: AIA Did Not Change Meaning Of On-Sa...
      • A generic pharma company had standing to appeal PT...
  • ►  2018 (4)
    • ►  December (1)
    • ►  October (1)
    • ►  August (1)
    • ►  July (1)
  • ►  2017 (63)
    • ►  December (2)
    • ►  November (2)
    • ►  October (2)
    • ►  August (5)
    • ►  July (9)
    • ►  June (4)
    • ►  May (10)
    • ►  April (4)
    • ►  March (13)
    • ►  February (7)
    • ►  January (5)
  • ►  2016 (23)
    • ►  December (5)
    • ►  November (6)
    • ►  October (3)
    • ►  September (9)

About Me

Paul Moradian's Pharma blog
View my complete profile
Payam Moradian's blog. Simple theme. Powered by Blogger.